Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Operates in Healthcare Services — In-patient & out-patient services. Per the activity note to the FY2024 annual report, the company provides medical services. Founded on 16 March 2000; wholly owned by Aversi-Pharma.
Subsidiary of Aversi-Pharma (100.0%)
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 80.2% | 78.6% | 79.6% | 76.6% | 73.6% | 79.6% | 83.4% | 85.2% |
| EBITDA Margin | 71.7% | 22.5% | 24.7% | 25.7% | 29.2% | 26.5% | 26.5% | 28.4% |
| EBITDAR | 34,566 | 13,159 | 16,100 | 17,136 | 28,125 | 24,355 | 25,825 | 32,785 |
| EBITDAR Margin | 72.6% | 23.4% | 25.0% | 26.0% | 29.5% | 26.8% | 26.7% | 28.6% |
| EBIT Margin | 59.3% | 12.7% | 15.8% | 15.6% | 21.6% | 16.4% | 15.9% | 17.9% |
| Net Profit Margin | 12.4% | 14.8% | 17.1% | 17.2% | 22.3% | 17.7% | 18.1% | 19.9% |
| Operating Expense % of Sales | 8.5% | 56.1% | 54.9% | 50.9% | 45.6% | 54.8% | 58.5% | 58.2% |
| Returns | ||||||||
| Return on Assets (ROA) | 9.6% | 12.9% | 14.6% | 14.1% | 21.0% | 14.1% | 13.5% | 14.7% |
| Return on Equity (ROE) | 11.4% | 13.9% | 16.5% | 15.7% | 24.3% | 15.5% | 15.5% | 17.5% |
| ROIC [EBIT / Invested Capital] | 56.3% | 12.9% | 15.9% | 15.4% | 24.1% | 16.5% | 16.6% | 17.6% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 84.3% | 92.7% | 88.5% | 90.3% | 86.6% | 90.5% | 86.9% | 83.9% |
| Net Debt | -1,258 | -4,093 | -2,935 | -5,649 | -1,863 | -12,922 | -19,951 | -13,743 |
| Cash & Equivalents | 1,258 | 4,093 | 2,935 | 5,649 | 1,863 | 12,922 | 19,951 | 13,743 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liquidity & working capital | ||||||||
| Current Ratio | 1.40x | 3.82x | 2.97x | 3.55x | 3.35x | 3.54x | 2.85x | 1.89x |
| Quick Ratio | 0.91x | 2.74x | 2.18x | 2.30x | 2.79x | 2.91x | 2.42x | 1.54x |
| Cash Ratio | 0.13x | 0.87x | 0.39x | 0.84x | 0.15x | 1.25x | 1.40x | 0.75x |
| Total Current Assets | 13,419 | 18,074 | 22,356 | 23,884 | 42,769 | 36,501 | 40,641 | 34,606 |
| Total Current Liabilities | 9,609 | 4,728 | 7,520 | 6,734 | 12,773 | 10,304 | 14,254 | 18,284 |
| Inventory | 4,640 | 5,116 | 5,951 | 8,377 | 7,071 | 6,564 | 6,215 | 6,362 |
| Trade Receivables | 7,521 | 8,865 | 13,470 | 9,858 | 33,836 | 17,015 | 17,621 | 32,190 |
| Trade Payables | 9,609 | 4,728 | 7,336 | 6,528 | 12,529 | 10,018 | 13,976 | 22,105 |
| Net Working Capital | 3,810 | 13,346 | 14,836 | 17,150 | 29,996 | 26,198 | 26,386 | 16,322 |
| Net Working Capital % of Revenue | 8.0% | 23.7% | 23.0% | 26.1% | 31.4% | 28.8% | 27.3% | 14.3% |
| Trade Working Capital | 2,552 | 9,253 | 12,085 | 11,707 | 28,378 | 13,561 | 9,860 | 16,447 |
| Trade Working Capital % of Revenue | 5.4% | 16.5% | 18.8% | 17.8% | 29.7% | 14.9% | 10.2% | 14.4% |
| Change in Trade Working Capital | N/A | 6,701 | 2,832 | -378 | 16,671 | -14,816 | -3,701 | 6,587 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 2.04x | 2.35x | 2.21x | 1.84x | 3.56x | 2.83x | 2.58x | 2.67x |
| Days Inventory Outstanding (DIO) | 179.3 | 155.5 | 165.3 | 198.2 | 102.6 | 129.1 | 141.7 | 136.7 |
| Receivables Turnover | 6.33x | 6.34x | 4.78x | 6.68x | 2.82x | 5.34x | 5.48x | 3.56x |
| Days Sales Outstanding (DSO) | 57.6 | 57.5 | 76.4 | 54.7 | 129.4 | 68.4 | 66.6 | 102.6 |
| Payables Turnover | 0.98x | 2.54x | 1.79x | 2.36x | 2.01x | 1.85x | 1.15x | 0.77x |
| Days Payable Outstanding (DPO) | 371.4 | 143.7 | 203.7 | 154.4 | 181.8 | 197.0 | 318.7 | 474.8 |
| Cash Conversion Cycle | -134.4 days | 69.3 days | 37.9 days | 98.4 days | 50.2 days | 0.4 days | -110.4 days | -235.5 days |
| Asset Turnover | 0.78x | 0.87x | 0.85x | 0.82x | 0.94x | 0.80x | 0.75x | 0.74x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 8,767 | 11,344 | 11,995 | 18,490 | 26,253 | 25,688 | 29,612 | 31,367 |
| Free Cash Flow (OCF − Capex proxy) | 8,767 | 2,836 | 2,951 | 8,749 | 2,454 | 11,601 | 15,626 | -963 |
| Cash Conversion (OCF / EBITDA) | 25.7% | 89.6% | 75.6% | 109.3% | 94.4% | 106.6% | 115.8% | 96.5% |
| Dividends Declared | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Payout Ratio | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →